SCT-200 is under clinical development by SinoCelltech Group and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SCT-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SCT-200 overview
SCT-200 is under development for the treatment of metastatic colorectal cancer, esophageal squamous cell carcinoma, squamous non-small cell lung cancer and recurrent head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The drug candidate is a monoclonal antibody. It acts by targeting the epidermal growth factor receptor (EGFR).
It was under development for the treatment of lymphoma, metastatic triple negative breast cancer, solid tumors including gastric cancer/gastroesophageal junction cancer, hepatocellular carcinoma, pancreatic cancer, bile duct/gallbladder cancer, renal cell carcinoma and ovarian cancer
SinoCelltech Group overview
SinoCelltech Group (SinoCelltech) is a biopharmaceutical and vaccine research and development company. The company’s activities include the development of biopharmaceuticals and vaccines. Its pipeline products include SCT800, SCT400, SCT400, SCT510, SCTV01, SCT-110A/PD-1, SCT1000/14, SCT650C/IL-17, SCTC21C/CD38 and SCTB35/CD20xCD3. SinoCelltech product indications include Hemophilia A, non-Hodgkin lymphoma, autoimmune disease, solid tumors, covid-19, solid and hematological tumors, cervical cancer, autoimmune disease, cd38-positive hematologic neoplasms and non-Hodgkin lymphoma. The company also carries out research and development activities in various diseases. SinoCelltech is headquartered in Beijing, China.
For a complete picture of SCT-200’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
